<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04696666</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-INST01F</org_study_id>
    <nct_id>NCT04696666</nct_id>
  </id_info>
  <brief_title>Tolerability and Efficacy of INSTYLAN in Subjects With Moderate to Severe Hemorrhagic Cystitis</brief_title>
  <official_title>Multicenter Clinical Study of the Efficacy and Tolerability of INSTYLAN (Sodium Hyaluronate 80mg/50ml) in Patients With Early or Late Symptoms of Moderate to Severe Hemorrhagic Cystitis Caused by Pelvic Radiation Therapy and/or Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LIDDE Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LIDDE Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and tolerability of INSTYLAN (Sodium&#xD;
      Hyaluronate 80mg/50ml) in Patients with early or late symptoms of moderate to severe&#xD;
      hemorrhagic cystitis caused by pelvic radiation therapy and/or chemotherapy. The study is&#xD;
      conducted in the field of routine clinical practice and will recruit 30 subjects treated with&#xD;
      intravesical instillations with INSTYLAN weekly for 6 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter single-arm clinical study including male and female subjects with&#xD;
      moderate to severe hemorrhagic cystitis caused by pelvic radiation therapy and/or&#xD;
      chemotherapy as determined by the physician. A total of 30 subjects are anticipated and will&#xD;
      be enrolled in 10 study sites in France.&#xD;
&#xD;
      The patients will receive intravesical instillations with INSTYLAN weekly for 6 weeks.&#xD;
&#xD;
      The objectives of the study are to assess the efficacy of intravesical instillations of&#xD;
      INSTYLAN on the basis of hemorrhagic cystitis symptoms disappearance. The primary endpoint is&#xD;
      the evaluation of pain using a verbal rating scale one week and four weeks after treatment&#xD;
      versus Baseline.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2020</start_date>
  <completion_date type="Anticipated">July 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>It is a multicenter single-arm clinical study aimed at assessing the efficacy and tolerability of INSTYLAN (Sodium Hyaluronate 80mg/50ml) provided in routine clinical practice in patients presenting with symptoms of moderate to severe hemorrhagic cystitis.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the intensity of bladder pain from the beginning of the study (baseline: Week 1) to Week 7</measure>
    <time_frame>Week 7</time_frame>
    <description>Questionnaire with 5 closed-ended response options: no pain, slight pain, moderate pain, severe pain, very severe pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the intensity of bladder pain from the beginning of the study (baseline: Week 1) to Week 10</measure>
    <time_frame>Week 10</time_frame>
    <description>Questionnaire with 5 closed-ended response options: no pain, slight pain, moderate pain, severe pain, very severe pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of hematuria following a rating scale</measure>
    <time_frame>Baseline, week 7 and week 10</time_frame>
    <description>Verbal rating scale of the colour of the urines: yellow, pink or red-brownish</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of number of micturitions / 24 hours</measure>
    <time_frame>Baseline, week 7 and week 10</time_frame>
    <description>Voiding diary sheet for each 24-hour period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of urgency of micturitions following a rating scale</measure>
    <time_frame>Baseline, week 7 and week 10</time_frame>
    <description>Verbal rating scale (slight, moderate, important)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hemorrhagic Cystitis</condition>
  <arm_group>
    <arm_group_label>Patients assigned in a single group and treated with 6 instillations of INSTYLAN for 6 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Group Assignment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>INSTYLAN (Sodium Hyaluronate 80mg/50ml)</intervention_name>
    <description>The bladder instillation with INSTYLAN is a treatment involving a sterile solution of Sodium Hyaluronate (80mg/50ml) inserted into the bladder through a catheter and released after a short period of time.</description>
    <arm_group_label>Patients assigned in a single group and treated with 6 instillations of INSTYLAN for 6 weeks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females, at least 18 years,&#xD;
&#xD;
          -  Patients who provided signed written informed consent, which includes compliance with&#xD;
             requirements listed in the consent form,&#xD;
&#xD;
          -  Patients with diagnosis of Hemorrhagic Cystitis,&#xD;
&#xD;
          -  Patients with diagnosis of bladder pain (pressure or pelvic discomfort) with at least&#xD;
             one other urinary symptom (need to urinate right away (urgency), often (frequency), or&#xD;
             both).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with Post-void residual (PVR) urine volume &gt; 200ml,&#xD;
&#xD;
          -  Patients presently treated with intravesical treatment (replenishment therapy with&#xD;
             glycosaminoglycans),&#xD;
&#xD;
          -  Patients receiving HyperBaric Oxygen Therapy (HBOT),&#xD;
&#xD;
          -  Patients with neurogenic bladder,&#xD;
&#xD;
          -  Patients treated with neuromodulation techniques within the last six months,&#xD;
&#xD;
          -  Patients undergoing or scheduled for radiation therapy, brachytherapy, chemotherapy or&#xD;
             treatment with BCG or with Mitomycin-C,&#xD;
&#xD;
          -  Patients suffering from lower urinary infections (UTIs),&#xD;
&#xD;
          -  Patients with unstable cardiovascular disease,&#xD;
&#xD;
          -  Patients with any other significant disease or disorder which, in the opinion of the&#xD;
             Investigator, may either put the participants at risk because of participation in the&#xD;
             trial, or may influence the result of the trial, or the participant's ability to&#xD;
             participate in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc FOURMARIER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aix en Provence Hospital Center (Aix en Provence)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>François SCHUTZE, PhD</last_name>
    <phone>+33 (0)6 83 54 01 42</phone>
    <email>fr.schutze@liddetherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aix en Provence Hospital Center</name>
      <address>
        <city>Aix-en-Provence</city>
        <zip>13616</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc FOURMARIER Principal Investigator, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ajaccio Hospital Center (Notre Dame de la Miséricorde)</name>
      <address>
        <city>Ajaccio</city>
        <zip>20167</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvain DUCROCQ Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Polyclinic Sainte Marguerite (Auxerre)</name>
      <address>
        <city>Auxerre</city>
        <zip>89000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nordine DEFFAR Investigator, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinic Rhône Durance (Avignon)</name>
      <address>
        <city>Avignon</city>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe CLEMENT Investigator, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cahors Hospital Center</name>
      <address>
        <city>Cahors</city>
        <zip>46000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Youssef BENTALEB Investigator, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinic of Val d'Ouest (Ecully)</name>
      <address>
        <city>Ecully</city>
        <zip>69130</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnaud CHERASSE Investigator, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mutualist Clinic Porte de l'Orient (Lorient)</name>
      <address>
        <city>Lorient</city>
        <zip>56100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre GRAZIANA Investigator, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinic Saint George (Nice)</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yohann ROUSCOFF Investigator, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Louis University Hospital Center (Paris)</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François MEYER Investigator, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regional University Hospital Center (Strasbourg)</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian SAUSSINE Investigator, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 3, 2021</study_first_submitted>
  <study_first_submitted_qc>January 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2021</study_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemorrhagic cystitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

